Allergan, an AbbVie Company, to Present Data from its Leading Portfolio of Eye Care Treatments at the 2022 American Glaucoma Society (AGS) Annual Meeting

Allergan, an AbbVie (NYSE: ABBV) company, today announced new data to be presented from Allergan’s leading portfolio of eye care treatments at the 2022 American Glaucoma Society (AGS) Annual Meeting being held in Nashville, TN and virtually from March 3-6. Presentations will include updated analyses that help further scientific understanding of DURYSTA® (bimatoprost intracameral implant), as well as new data on the XEN® Gel Stent. The DURYSTA data presentations coincide with the two-year anniversary of the U.S. Food and Drug Administration (FDA) approval of this first-of-its-kind eye pressure lowering treatment for glaucoma patients in March 2020.

“Glaucoma is one of the primary causes of irreversible vision loss and blindness worldwide. We are proud of our portfolio that provides treatments to glaucoma patients at different stages of their disease, but know there is still work to be done,” said Michael R. Robinson, M.D., vice president, global therapeutic area head, eye care, AbbVie. “At AGS 2022 we will build on the growing body of knowledge around DURYSTA two years after its FDA approval, and present additional data about XEN investigating potential new uses of the gel stent that may improve glaucoma patient outcomes.”

Data to be presented include a new study comparing the efficacy and safety of the XEN Gel Stent to trabeculectomy, as well as data from the EXPAND study evaluating the real-world effectiveness and safety of a novel investigational placement of the stent. The XEN Gel Stent is FDA-cleared only for ab-interno placement.

Researchers will also present data from an ongoing 24-month extension study of the Phase 3 ARTEMIS study assessing the efficacy and duration of DURYSTA. DURYSTA was approved by the FDA in March 2020 to reduce eye pressure, or intraocular pressure (IOP), in patients with open angle glaucoma (OAG) or high eye pressure (ocular hypertension, or OHT). Findings from a study documenting DURYSTA’s impact on IOP over a 24-hour period will also be presented at the meeting.

A complete listing of the Allergan abstracts that are scheduled to be presented at the 2022 AGS Annual Meeting can be viewed at https://www.xcdsystem.com/ags/program/S9oEr0i/index.cfm.

Details about Allergan’s presentations are as follows:

AbstractPresentation DetailsAll Times CST
Prospective, Randomized, Multicenter, Open-label, 12-Month Evaluation of the Effectiveness and Safety of XEN45 vs Trabeculectomy: the Gold Standard Pathway Study (GPS)Session: Top Posters Virtual Presentation with Q&ASaturday, March 57:00 – 8:30 a.m.
Bimatoprost Implant Effects on 24-Hour Intraocular PressureSession: Top Posters Virtual Presentation with Q&ASaturday, March 57:00 – 8:30 a.m.
Retrospective, multicenter, real-world evaluation of ab-externo gel stent placement: 12-month data from the EXPAND StudySession: Top Posters Virtual Presentation with Q&ASaturday, March 57:00 – 8:30 a.m.
Extended Duration of IOP Lowering with Bimatoprost Implant in a Phase 3 Extension StudySession: Paper Presentations: Treatment – Live Q&A*Note: Presentation pre-recorded and available on demandSaturday, March 59:00 – 9:40 a.m.Summit Ballroom

DURYSTA® Consumer Indications and Usage and Important Safety Information

Approved Uses
DURYSTA® (bimatoprost intracameral implant) is a prescription medicine to reduce eye pressure (also called intraocular pressure, or IOP) in patients with open angle glaucoma or high eye pressure (ocular hypertension).

About Allergan Eye Care
As a leader in eye care, Allergan has discovered, developed, and delivered some of the most innovative products in the industry for more than 70 years. Allergan has launched over 125 eye care products and invested billions of dollars in treatments for the most prevalent eye conditions including glaucoma, ocular surface disease, and retinal diseases such as diabetic macular edema and retinal vein occlusion.

About AbbVie
AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.

Source link:https://news.abbvie.com/